Masuo Kazuko, Rakugi Hiromi, Ogihara Toshio, Esler Murray D, Lambert Gavin W
Nucleus Network Ltd., Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria 3004, Australia.
Curr Diabetes Rev. 2010 Mar;6(2):58-67. doi: 10.2174/157339910790909396.
Overweight and obesity is a growing "world-wide epidemic problem". Because as many as, two-thirds of the adult population and a growing number of children are overweight. The prevalence of diabetes, especially type 2 diabetes and hypertension have significantly increased with the prevalence of obesity. Obesity accompanying type 2 diabetes and hypertension are known to be closely linked with insulin resistance and elevated sympathetic nervous activity. It has been well documented that obesity, hypertension, and diabetes are high risk factors for subsequent cardiovascular and renal complications. Many patients are both diabetic and hypertensive, while they are obese, but not all diabetic patients have hypertension, indicating that insulin resistance is not only a mechanism for blood pressure elevation in diabetic-hypertensive patients. Several investigators have reported that sympathetic nervous activation relates to cardiovascular complications in patients with hypertension, diabetes, and obesity, and that sympathetic nerve activity accompanying insulin resistance is closely linked with left ventricular hypertrophy in healthy subjects. In addition, sympathetic nerve activation may predict future renal injury in healthy normotensive subjects. These findings suggest that elevated sympathetic nerve activity associated with insulin resistance may contribute to the onset and maintenance of cardiovascular and renal complications in diabetes, and hypertension in obesity. Further, genetic polymorphisms of the beta2- and beta3-adrenoceptor gene have been associated with type-2 diabetes and insulin resistance in many epidemiological studies and might be another factor responsible for the close relationship between insulin resistance and heightened sympathetic nerve activity. Thus, focusing on the interactions between insulin resistance, sympathetic nervous activity and beta-adrenoceptor polymorphisms might help in understanding the precise relationships between insulin resistance and sympathetic nerve activity in type 2 diabetes and obesity-related hypertension. The purpose of this article is to provide a synthesis of the current findings on the mechanisms of the onset and maintenance of cardiovascular and renal complications in obesity, diabetes and hypertension. A better understanding of the relationships of sympathetic nervous system activity and insulin resistance might help with the clinical treatment of diabetes and hypertension in obesity. Further, to clarify the pathogenesis and mechanisms of the association between obesity, diabetes, and hypertension may lead to reductions in cardiovascular and renal risk.
超重和肥胖是一个日益严重的“全球性流行问题”。因为多达三分之二的成年人口以及越来越多的儿童超重。随着肥胖患病率的上升,糖尿病,尤其是2型糖尿病和高血压的患病率显著增加。已知伴有2型糖尿病和高血压的肥胖与胰岛素抵抗和交感神经活动增强密切相关。大量文献记载,肥胖、高血压和糖尿病是随后发生心血管和肾脏并发症的高危因素。许多患者既患有糖尿病又患有高血压,同时还肥胖,但并非所有糖尿病患者都患有高血压,这表明胰岛素抵抗不仅是糖尿病合并高血压患者血压升高的一种机制。几位研究人员报告说,交感神经激活与高血压、糖尿病和肥胖患者的心血管并发症有关,并且健康受试者中伴随胰岛素抵抗的交感神经活动与左心室肥厚密切相关。此外,交感神经激活可能预测健康血压正常受试者未来的肾损伤。这些发现表明,与胰岛素抵抗相关的交感神经活动增强可能有助于糖尿病患者心血管和肾脏并发症以及肥胖患者高血压的发生和维持。此外,在许多流行病学研究中,β2和β3肾上腺素能受体基因的遗传多态性与2型糖尿病和胰岛素抵抗有关,可能是导致胰岛素抵抗与交感神经活动增强密切关系的另一个因素。因此,关注胰岛素抵抗、交感神经活动和β肾上腺素能受体多态性之间的相互作用可能有助于理解2型糖尿病和肥胖相关高血压中胰岛素抵抗与交感神经活动之间的精确关系。本文的目的是综合目前关于肥胖、糖尿病和高血压中心血管和肾脏并发症发生和维持机制的研究结果。更好地理解交感神经系统活动与胰岛素抵抗之间的关系可能有助于肥胖患者糖尿病和高血压的临床治疗。此外,阐明肥胖、糖尿病和高血压之间关联的发病机制可能会降低心血管和肾脏风险。